Silver Oak Securities Incorporated Purchases Shares of 1,575 Stryker Co. (NYSE:SYK)

Silver Oak Securities Incorporated acquired a new position in shares of Stryker Co. (NYSE:SYK) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,575 shares of the medical technology company’s stock, valued at approximately $571,000.

A number of other hedge funds have also modified their holdings of SYK. Dunhill Financial LLC increased its stake in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Stryker in the third quarter worth approximately $36,000. Crews Bank & Trust acquired a new stake in shares of Stryker during the fourth quarter valued at approximately $39,000. Hara Capital LLC acquired a new position in Stryker in the 3rd quarter worth approximately $42,000. Finally, Grove Bank & Trust grew its position in Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 1.2 %

Shares of Stryker stock opened at $391.42 on Friday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a 50 day moving average price of $377.25 and a two-hundred day moving average price of $364.47. The stock has a market capitalization of $149.22 billion, a P/E ratio of 50.44, a PEG ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 earnings per share. Equities analysts expect that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s payout ratio is 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SYK shares. Canaccord Genuity Group increased their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. The Goldman Sachs Group raised their price objective on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $370.00 to $445.00 in a report on Monday, December 2nd. BTIG Research raised their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.